Tag: YS Biopharma
China’s YishengBio eyes US capital markets via SPAC route
Yisheng Biopharma has abandoned its Hong Kong IPO and turned instead to the Nasdaq via the SPAC route in a deal that is expected to be sealed by the first quarter of 2023
Yisheng Biopharma has abandoned its Hong Kong IPO and turned instead to the Nasdaq via the SPAC route in a deal that is expected to be sealed by the first quarter of 2023
Like never before, the turnstyle of law firm exits and entries provides a barometer for regional business
Join our mailing list for legal news and alerts
Sign up